- A 149-subject Phase 3b clinical trial assessing Eli Lilly's (NYSE:LLY) Taltz (ixekizumab) in patients with moderate-to-severe genital psoriasis showed a treatment benefit. Specifically, patients in the treatment group experienced a reduced impact on sexual activity compared to placebo after 12 weeks of treatment. The results were presented at AAD in San Diego.
- 92.0% of patients in the treatment group reported no or little sexual difficulties caused by skin symptoms compared to 56.8% for placebo (p<0.001). 78.4% of patients receiving Taltz reported that the frequency of sexual activity was either never or rarely limited by genital psoriasis versus 21.4% for placebo (p<0.001).
- Up to 63% of psoriasis sufferers experience symptoms in the genital area.
- Taltz is currently approved in the U.S. for the treatment of plaque psoriasis and psoriatic arthritis.
- Now read: Eli Lilly: Solid 2017, Soft Sales Guidance
Original article